UCB SA (OTCMKTS:UCBJY – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $93.61 and traded as high as $96.26. UCB shares last traded at $94.31, with a volume of 38,479 shares changing hands.
UCB Stock Performance
The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The company has a 50-day moving average of $97.49 and a 200-day moving average of $93.66.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Featured Stories
- Five stocks we like better than UCB
- Top Stocks Investing in 5G Technology
- Symbotic Shares Down 37%—Is It Time for Bravery or Caution?
- What is the Dogs of the Dow Strategy? Overview and Examples
- High-Yield Healthcare: 3 Stocks With Strong Dividends
- What is the Hang Seng index?
- Beyond the Bargain Bin: 3 Stocks Leading Discount Retail
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
